James E Dentzer - Net Worth and Insider Trading

James E Dentzer Net Worth

The estimated net worth of James E Dentzer is at least $14,436 dollars as of 2024-11-29. James E Dentzer is the President & CEO of Curis Inc and owns about 3,244 shares of Curis Inc (CRIS) stock worth over $14,436. Details can be seen in James E Dentzer's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that James E Dentzer has not made any transactions after 2022-01-31 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of James E Dentzer

James E Dentzer Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, James E Dentzer owns 4 companies in total, including Curis Inc (CRIS) , Dicerna Pharmaceuticals Inc (DRNA) , and Amicus Therapeutics Inc (FOLD) among others .

Click here to see the complete history of James E Dentzer’s form 4 insider trades.

Insider Ownership Summary of James E Dentzer

Ticker	Comapny	Transaction Date	Type of Owner
CRIS	Curis Inc	2023-01-20	director & President & CEO
DRNA	Dicerna Pharmaceuticals Inc	2015-01-09	Chief Financial Officer
FOLD	Amicus Therapeutics Inc	2007-05-30	Chief Financial Officer
		2022-09-29	director

James E Dentzer Latest Holdings Summary

James E Dentzer currently owns a total of 1 stock. James E Dentzer owns 3,244 shares of Curis Inc (CRIS) as of January 31, 2022, with a value of $14,436.

Latest Holdings of James E Dentzer

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
CRIS	Curis Inc	2022-01-31	3,244	4.45	14,436

Holding Weightings of James E Dentzer

James E Dentzer Form 4 Trading Tracker

According to the SEC Form 4 filings, James E Dentzer has made a total of 3 transactions in Curis Inc (CRIS) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Curis Inc is the sale of 275 shares on January 31, 2022, which brought James E Dentzer around $17,160.

Insider Trading History of James E Dentzer

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

James E Dentzer Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

James E Dentzer Ownership Network

Ownership Network List of James E Dentzer

No Data

Ownership Network Relation of James E Dentzer

James E Dentzer Owned Company Details

What does Curis Inc do?

Who are the key executives at Curis Inc?

James E Dentzer is the director & President & CEO of Curis Inc. Other key executives at Curis Inc include CDO Jonathan B. Zung , CFO Diantha Duvall , and Head of Research & Development Robert Martell .

Curis Inc (CRIS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Curis Inc (CRIS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Curis Inc (CRIS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Curis Inc (CRIS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Curis Inc Insider Transactions

No Available Data

What does Dicerna Pharmaceuticals Inc do?

Who are the key executives at Dicerna Pharmaceuticals Inc?

James E Dentzer is the Chief Financial Officer of Dicerna Pharmaceuticals Inc. Other key executives at Dicerna Pharmaceuticals Inc include See Remarks Bob D Brown , EVP & Chief Medical Officer Shreeram Aradhye , and director & President and CEO Douglas Fambrough .

Dicerna Pharmaceuticals Inc (DRNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dicerna Pharmaceuticals Inc (DRNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dicerna Pharmaceuticals Inc (DRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dicerna Pharmaceuticals Inc (DRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dicerna Pharmaceuticals Inc Insider Transactions

No Available Data

What does Amicus Therapeutics Inc do?

Who are the key executives at Amicus Therapeutics Inc?

James E Dentzer is the Chief Financial Officer of Amicus Therapeutics Inc. Other key executives at Amicus Therapeutics Inc include director & President and CEO Bradley L Campbell , director & Executive Chairman John F Crowley , and Chief People Officer David Michael Clark .

Amicus Therapeutics Inc (FOLD) Insider Trades Summary

Over the past 18 months, James E Dentzer made no insider transaction in Amicus Therapeutics Inc (FOLD). Other recent insider transactions involving Amicus Therapeutics Inc (FOLD) include a net sale of 232,762 shares made by Bradley L Campbell , a net sale of 327,191 shares made by John F Crowley , and a net sale of 95,000 shares made by Ellen Rosenberg .

In summary, during the past 3 months, insiders sold 30,401 shares of Amicus Therapeutics Inc (FOLD) in total and bought 0 shares, with a net sale of 30,401 shares. During the past 18 months, 797,737 shares of Amicus Therapeutics Inc (FOLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 797,737 shares.

Amicus Therapeutics Inc (FOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Amicus Therapeutics Inc Insider Transactions

No Available Data

What does Imunon Inc do?

Who are the key executives at Imunon Inc?

James E Dentzer is the director of Imunon Inc. Other key executives at Imunon Inc include Chief Executive Offier Michael H Tardugno , director & President and CEO Le Goff Corinne , and Chief Accounting Officer Kardaras Constantine John .

Imunon Inc (IMNN) Insider Trades Summary

Over the past 18 months, James E Dentzer made no insider transaction in Imunon Inc (IMNN). Other recent insider transactions involving Imunon Inc (IMNN) include a net purchase of 25,000 shares made by Michael H Tardugno , and a net purchase of 25,000 shares made by Stacy Lindborg .

In summary, during the past 3 months, insiders sold 0 shares of Imunon Inc (IMNN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Imunon Inc (IMNN) were sold and 50,000 shares were bought by its insiders, resulting in a net purchase of 50,000 shares.

Imunon Inc (IMNN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Imunon Inc Insider Transactions

No Available Data

James E Dentzer Mailing Address

Above is the net worth, insider trading, and ownership report for James E Dentzer. You might contact James E Dentzer via mailing address: C/o Amicus Therapeutics, Inc., 6 Cedar Brook Drive, Cranbury Nj 08512.

Discussions on James E Dentzer

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.